Medical Grade CBD Infused Skin Care Products, From Dermesse
Axia Medical Solutions LLC, a California licensed Wholesale Drug Distributor, has launched the first medical grade skin care products containing cannabidiol (CBD). This new line of products was created by taking their existing physician based Dermesse products and infusing them with high-quality CBD. Their water-soluble CBD is free of any THC which is the psychoactive component found in hemp.
Axia Medical created this line due to all the positive reviews concerning the benefits of topically applied CBD creams which range from anti-inflammatory and antioxidant properties to pain relief and anti-aging claims. The inclusion of CBD helps add another level of efficacy to the already well-known benefits of the Dermesse brand.
Even though medical marijuana and CBD products have been prevalent in the news lately, the acceptance in the market for CBD products has been slow due to consumer concerns of safety. According to James Krulisky, President and CEO, “consumers are skeptical because of all the CBD products that are on the market and that these products might be mislabeled, not tested, provide minimal information, or produced and distributed by questionable sources. Axia Medical’s credibility as a licensed Wholesale Drug Distributor, has removed all these concerns. The Dermesse CBD has been rigorously tested, is safe for topical use, protected from oxidation in airless pumps, will not create a ‘high,’ and is not addicting.”
This new formulation of CBD infused products will add to the already extensive line of Dermesse products which include prescription drugs, OTC drugs, and cosmetics. Axia maintains the highest standards and validates every aspect of the manufacturing process, ensures compliance with all state and federal regulations, and provides documentation on their website.
About Axia Medical Solutions: Axia Medical Solutions was formed in 2003 as a specialty pharmaceutical company providing prescription-strength drugs, over-the-counter drugs, and cosmetic skin care products to the medical professional community under the brand name, Dermessetm. Axia Medical is a California licensed Wholesale Drug Distributor, maintains distributor licenses throughout the USA, and is accredited by the National Association of Boards of Pharmacy VAWD program
Are CBD skincare products effective?
A variety of topical CBD products are becoming increasingly available to patients, but do they actually work? These experts believe more research is needed to create CBD-containing dermatology products that can effectively treat skin disorders.
“Currently, there aren’t many high-quality, high-standard CBD products on the market,” says Michael Milane, M.D., MBA, MPH, chief executive officer of Greenway Therapeutix, a company focused on developing novel dermatology therapeutics. “There’s a lot of hype out there, but it’s still the Wild West. For the most part, they don’t reach the standards we’re accustomed to in dermatology.”
To date, most CBD products haven’t provided much therapeutic effect, Dr. Milane says. In most instances, they don’t contain enough CBD to be significantly impactful. And, there’s no existing data identifying the best CBD concentration.
Additionally, CBD is most often included in oil solutions or emulsions, and the molecules respond exactly like oil when it touches water – it clumps up, making it impossible for CBD to penetrate the skin. Greenway Therapeutix is actively trying to solve this problem, he says.
“Barrier penetration is an issue,” he says. “We’ve put a lot of nanotechnology science into making CBD component penetration in these products a lot more feasible.”
So far, they’ve been successful in reducing the symptoms of atopic dermatitis and acne. Clinical testing is still underway, he says.
HOW IT WORKS
The human body is naturally equipped to respond to CBD through its endocannabanoid system, Dr. Milane explains. With two major receptor sites – CB1 and CB2 – cannabanoids bind to it much like a lock-and-key. When the system activates, it plays a key role in regulating inflammation, pain perception, immunity, neuropathy and metabolism. Specifically, the CB2 receptor reduces the concentration of pro-inflammatory cytokines interleukin-6 and tumor necrosis factor-alpha.
Of all cannabanoids, he says, CBD has been the most thoroughly investigated for its therapeutic potential. Current data points to high anti-inflammatory properties on multiple skin targets, including keratinocytes, dermal immune cells, sensory neurons, sebocytes and hair follicles. Additionally, clinical observations have revealed CBD reduces redness and itching within 10 minutes of application. It’s these impacts that are critical in treating skin disorders, Dr. Milane says.
“Inflammation and inflammatory disorders are a significant part of dermatological disease,” he says. “If we can find potential in a different pathway other than steroids, which are heavily used for anti-inflammatory properties, then it would be a huge advantage for us.”
Unlike steroids, existing research shows CBD is safe for all populations – children, adolescents, adults, and the elderly. It can be used on almost any body area, and it doesn’t cause any side effects that limit how long it can be used to treat skin conditions.
While current products on the market don’t provide a satisfactory therapeutic effect, initial clinical trials show CBD may be a safe, effective treatment for skin disorders, says Daniel Siegel, M.D., M.S., clinical dermatology professor at State Univeristy of New York Downstate Medical Center. According to Greenway Therapeutix testing, the most substantial improvements appeared in reducing atopic dermatitis symptoms.
“With atopic dermatitis, the associated itch goes away within minutes of application, and the lesions disappear within a day or two of once or twice-daily use,” says Dr. Siegel, who has worked with Dr. Milane on Greenway Therapeutix endeavors. “It does seem to have a beneficial effect. Think of it as a drug to replace steroids in places you don’t want to use steroids.”
Alongside the company’s nanotechnology option, atopic dermatitis is also treated with a 2% topical adelmidrol emulsion. A 3% cannabis seed topical cream has been used to reduce inflammation and sebocyte production in patients with acne. And, a 3% CBD topical has been applied to reduce inflammation and suppress keratinocyte proliferation in patients with psoriasis.
In a market with few high-standard CBD options, Dr. Siegel says, providers should educate themselves even if they don’t intend to recommend the products.
“My advice to providers who strive to maintain the highest standard of ethics is to be aware there aren’t any products out there right now that really deliver the expected effect,” Dr. Siegel says. “If you use topical CBD products now, you’ll likely be unimpressed.”
The market could change within a year, he says. Meanwhile, he cautions providers to examine patients who use these products for contact dermatitis.
Despite the lack of high-quality products, Dr. Milane says, providers should expect an increasing number of patients to inquire about them.